Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia-Reference-Cited by-同舟云学术

Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia

Published:2017-11-06 Issue:1 Volume:11 Page:4-15
ISSN:1940-6207
Container-title:Cancer Prevention Research
language:en
Short-container-title:Cancer Prev Res

Author:

Delker Don A.,Wood Austin C.,Snow Angela K.,Samadder N. Jewel,Samowitz Wade S.,Affolter Kajsa E.,Boucher Kenneth M.,Pappas Lisa M.,Stijleman Inge J.,Kanth Priyanka,Byrne Kathryn R.,Burt Randall W.,Bernard Philip S.,Neklason Deborah W.

Funder

NIH

NCI

National Cancer Institute

National Center for Advancing Translational Sciences

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Helicobacter pylori infection with colorectal polyps/adenomas: A single-center cross-sectional study;Cancer Epidemiology;2024-10

2. Erlotinib suppresses tumorigenesis in a mouse model of colitis-associated cancer;Biomedicine & Pharmacotherapy;2024-06

3. Which Drugs are More Effective in Preventing Familial Adenomatous Polyposis Progression based on Network Meta-analysis?;Current Pharmaceutical Design;2024-06

4. Evaluation of EGFR and COX pathway inhibition in human colon organoids of serrated polyposis and other hereditary cancer syndromes;Familial Cancer;2024-04-12

5. Abstract 5276: Immunomodulatory activity of intermittent low-dose erlotinib plus sulindac: Implications for hereditary and sporadic colorectal cancer;Cancer Research;2024-03-22